Thursday, September 24, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Regulatorybpc-157tb-500fdawadarfk jr

Outside reviews BPC-157 and TB-500 hype as FDA panel weighs looser rules

The magazine notes WADA banned the compounds in 2022 and that human clinical evidence for the "Wolverine Stack" is essentially absent.

DO
By Daniel Okafor · Regulatory Correspondent
Sep 24 03:32 ETSource: Outside Magazine

The wire

  1. 01The piece describes a July FDA advisory panel that voted against expert advice to recommend loosening restrictions on six popular peptides, and quotes HHS Secretary Robert F. Kennedy Jr. saying he is "a big fan" of peptides.
  2. 02Athletes buying injectable BPC-157 and TB-500 online face unregulated products; the article says long-term effects are unknown and cites scientist-raised theoretical cancer risk.
  3. 03Pharmacology sources quoted warn that approval would not guarantee product quality and could draw more unsanctioned suppliers; the article presents no new clinical data.

From the source

Peptides: Huge Promises, Unproven Hype

What if you could recover from your bike workouts as fast as Wolverine, the self-healing super-mutant who plays antihero of the Marvel Universe?

Read at velo.outsideonline.com
PeptiPrescribed peptides from $99/moSee all →